ASCO 2018: Improved Overall Survival with Adjuvant mFOLFIRINOX in Resected Pancreatic Cancer
7 Jun, 2018 | 02:38h | UTCAdjuvant mFOLFIRINOX vs Gemcitabine in Resected Pancreatic Cancer – The ASCO Post (free)
Related: Pancreatic Cancer Survival Jumps With Postsurgical Chemo Combo – OncLive (free) AND Study Finds Rare Gain for Tough-To-Treat Pancreatic Cancer – Associated Press (free)